Sept 19 (Reuters) - BioXcel Therapeutics Inc :
* BIOXCEL THERAPEUTICS INC - PLAN TO REDUCE ITS WORKFORCE BY 15 EMPLOYEES, OR ABOUT 28% OF COMPANY'S HEADCOUNT
* BIOXCEL THERAPEUTICS: PLAN TO REDUCE WORKFORCE TO EXTEND ITS CASH RUNWAY, PRIORITIZE INVESTMENT ON CLINICAL DEVELOPMENT OF ITS BXCL501
* BIOXCEL THERAPEUTICS INC - ESTIMATES IT WILL INCUR AGGREGATE CHARGES IN CONNECTION WITH CLINICAL PRIORITIZATION OF ABOUT $1.4 MILLION
* BIOXCEL THERAPEUTICS - SEES MAJORITY OF COSTS TO BE INCURRED, CLINICAL PRIORITIZATION IS EXPECTED TO BE COMPLETED, DURING QUARTER ENDING DECEMBER 31
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.